Observation vs. targeted high-dose radiation for metastatic prostate cancer

0
7


What The Study Did: This randomized clinical trial compared how effectively high-dose, targeted radiation therapy versus no treatment (observation) among 54 men prevented the progression over six months of recurrent hormone-sensitive prostate cancer that has metastasized to a small number of sites in the body.

Authors: Phuoc T. Tran, M.D., Ph.D., of the Johns Hopkins University School of Medicine in Baltimore, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ 

(doi:10.1001/jamaoncol.2020.0147)

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

###

Media advisory: The full study and commentary are linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2020.0147?guestAccessKey=e5501192-c562-4e38-9167-81da44e28982&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=032620

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here